Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
263 hedge funds and large institutions have $5.69B invested in Blueprint Medicines in 2021 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 103 increasing their positions, 93 reducing their positions, and 46 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 93
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
1.73% less ownership
Funds ownership: 102.68% → 100.96% (-1.7%)
5% less funds holding
Funds holding: 278 → 263 (-15)
12% less capital invested
Capital invested by funds: $6.46B → $5.69B (-$770M)
24% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 46
51% less call options, than puts
Call options by funds: $8.55M | Put options by funds: $17.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$69.4M |
| 2 |
Jennison Associates
New York
|
+$39.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$36.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$32.7M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$30.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$51.1M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$22.2M |
| 3 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
-$18.6M |
| 4 |
Morgan Stanley
New York
|
-$17.2M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$15.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAAS
301
Capital Asset Advisory Services
Williamston,
Michigan
| – | -$19K | -168 | Closed |
|
|
SNT
302
Security National Trust
Wheeling,
West Virginia
| – | -$6K | -52 | Closed |
|
|
ABC
303
Associated Banc-Corp
Green Bay,
Wisconsin
| – | -$4K | -36 | Closed |
|
|
ASN
304
Advisory Services Network
Atlanta,
Georgia
| – | -$3K | -31 | Closed |
|
|
CFGS
305
Concourse Financial Group Securities
Birmingham,
Alabama
| – | -$2.5K | -25 | Closed |
|
|
ICP
306
Interchange Capital Partners
Pittsburgh,
Pennsylvania
| – | -$2K | -23 | Closed |
|
|
PFGIA
307
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
| – | -$1.4K | -14 | -78% |
|
308
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
| – | -$1K | -7 | Closed |
|
|
GWSG
309
GPS Wealth Strategies Group
Centennial,
Colorado
| – | +$799 | +8 | New |
|
BPMC Hedge Fund Activity: Q1 2021 in Review
263 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2021, worth a combined $5.69B — down 12% from $6.46B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of BPMC and 35 opened new positions — a net loss of 11 holders — while 93 trimmed existing stakes and 103 added.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $69.4M. The largest seller was HHLR Advisors, cutting an estimated $51.1M.
- 263 institutional investors held Blueprint Medicines (BPMC) as of Q1 2021, down from 278 in Q4 2020.
- Funds reported $5.69B of Blueprint Medicines stock for Q1 2021, down 12% quarter-over-quarter.
- 35 funds opened new Blueprint Medicines positions in Q1 2021 and 46 closed out, a net change of -11 holders.
- The largest Blueprint Medicines buyer in Q1 2021 was Farallon Capital Management, an estimated $69.4M added.
- The largest Blueprint Medicines seller in Q1 2021 was HHLR Advisors, an estimated $51.1M sold.
Based on aggregated 13F filings for Q1 2021.